Cargando…

T Cell Dysfunction in Cancer Immunity and Immunotherapy

In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Anliang, Zhang, Yan, Xu, Jiang, Yin, Tailang, Lu, Xiao-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659036/
https://www.ncbi.nlm.nih.gov/pubmed/31379886
http://dx.doi.org/10.3389/fimmu.2019.01719
_version_ 1783439056480239616
author Xia, Anliang
Zhang, Yan
Xu, Jiang
Yin, Tailang
Lu, Xiao-Jie
author_facet Xia, Anliang
Zhang, Yan
Xu, Jiang
Yin, Tailang
Lu, Xiao-Jie
author_sort Xia, Anliang
collection PubMed
description In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex tumor microenvironment, tumor-specific T cells have distinct dysfunction states. Therapeutic reactivation of tumor-specific T cells has yielded good results in cancer patients. Here, we review the hallmarks of T cell dysfunction in cancer. Also, we discuss the relationship between T cell dysfunction and cancer immunotherapy.
format Online
Article
Text
id pubmed-6659036
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66590362019-08-02 T Cell Dysfunction in Cancer Immunity and Immunotherapy Xia, Anliang Zhang, Yan Xu, Jiang Yin, Tailang Lu, Xiao-Jie Front Immunol Immunology In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex tumor microenvironment, tumor-specific T cells have distinct dysfunction states. Therapeutic reactivation of tumor-specific T cells has yielded good results in cancer patients. Here, we review the hallmarks of T cell dysfunction in cancer. Also, we discuss the relationship between T cell dysfunction and cancer immunotherapy. Frontiers Media S.A. 2019-07-19 /pmc/articles/PMC6659036/ /pubmed/31379886 http://dx.doi.org/10.3389/fimmu.2019.01719 Text en Copyright © 2019 Xia, Zhang, Xu, Yin and Lu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xia, Anliang
Zhang, Yan
Xu, Jiang
Yin, Tailang
Lu, Xiao-Jie
T Cell Dysfunction in Cancer Immunity and Immunotherapy
title T Cell Dysfunction in Cancer Immunity and Immunotherapy
title_full T Cell Dysfunction in Cancer Immunity and Immunotherapy
title_fullStr T Cell Dysfunction in Cancer Immunity and Immunotherapy
title_full_unstemmed T Cell Dysfunction in Cancer Immunity and Immunotherapy
title_short T Cell Dysfunction in Cancer Immunity and Immunotherapy
title_sort t cell dysfunction in cancer immunity and immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659036/
https://www.ncbi.nlm.nih.gov/pubmed/31379886
http://dx.doi.org/10.3389/fimmu.2019.01719
work_keys_str_mv AT xiaanliang tcelldysfunctionincancerimmunityandimmunotherapy
AT zhangyan tcelldysfunctionincancerimmunityandimmunotherapy
AT xujiang tcelldysfunctionincancerimmunityandimmunotherapy
AT yintailang tcelldysfunctionincancerimmunityandimmunotherapy
AT luxiaojie tcelldysfunctionincancerimmunityandimmunotherapy